COMPANY PROFILE

Bilix

Explore full profile

The World’s First PEGylated Bilirubin Technology

Yongin-si, South KoreaFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Bilix

Bilix operates in the biotechnology sector, leveraging its proprietary PEGylated bilirubin platform technology to develop advanced therapies for intractable inflammatory diseases and cancer. The company's core product, the BRIXELLE Platform, is designed to create highly potent and less toxic drug delivery systems, as well as theranostic applications, which combine therapy and diagnostics. Bilix serves a diverse range of clients, including research organizations, clinical development entities, hospitals, and patient advocacy groups. The company generates revenue through the development and commercialization of its innovative drug delivery systems and diagnostic agents. Bilix's business model focuses on collaboration with various stakeholders in the healthcare ecosystem to bring its cutting-edge therapies to market. The company aims to improve patient health and care by providing effective and safer treatment options for complex diseases.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Yongin-si, South Korea
Employees: 9
Open positions: None listed
Dealroom signal: 68.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Oncology, Drug Development, Inflammatory Diseases, Spinout, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jul 2025	$24M	$98M	Undisclosed	↗
OtherOther financing	Jan 2019	$0	—	Alpenroute Asset Management	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Bilix website traffic

Latest recorded traffic for Bilix is 1.2K monthly website visits, up 79.1% over the last three months. Bilix's team declined 10% over the past year.

Latest monthly visits1.2K 3-month web change+79.1% 1-year team growth-10%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EVEvotecDrug discovery and development for pharma and biotech	Hamburg, Germany	Operational	4,712	$54M	$641M
MIMironidSmall molecule therapeutics for hereditary kidney disease	Glasgow, United Kingdom	Operational
BIBiomXCustomized phage therapies to eradicate harmful bacteria in chronic diseases	Ness Ziona, Israel	Operational
MBMetri BioTherapeutics for endometrial diseases using 3D modeling	Boston, United States	Operational
BNBNanoTechNanoparticle technology for targeted central nervous system drug delivery	Porto, Portugal	Operational
AUAutomeratxDeveloping the next evolution in degradation platforms	Singapore	Operational
MTMestag TherapeuticsDeveloping antibody therapeutics targeting fibroblast-immune interactions	Little Chesterford, United Kingdom	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational